First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma

Ravi Vij, Rajneesh Nath, Daniel E.H. Afar, María Victoria Mateos, Jesus G. Berdeja, Marc S. Raab, Andreas Guenther, Joaquín Martínez-Lopez, Andrzej J. Jakubowiak, Xavier Leleu, Katja Weisel, Shekman Wong, Scott Gulbranson, James P. Sheridan, Anita Reddy, Bruno Paiva, Anil Singhal, Jesus F. San-Miguel, Philippe Moreau

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Purpose: ABBV-838 is an antibody–drug conjugate targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells. This phase I/Ib first-inhuman, dose-escalation study (trial registration ID: NCT02462525) evaluated the safety, pharmacokinetics, and preliminary activity of ABBV-838 in patients with relapsed and refractory multiple myeloma (RRMM). Patients and Methods: Eligible patients (≥18 years) received ABBV-838 (3þ3 design) intravenously starting from 0.6 mg/kg up to 6.0 mg/kg for 3-week dosing intervals (Q3W). Patients could continue ABBV-838 for up to 24 months. Assessment of alternate dosing intervals (Q1W and Q2W) was conducted in parallel. Results: As of March 2017, 75 patients received at least one dose of ABBV-838. The most common any-grade treatment-emergent adverse events (TEAE) were neutropenia and anemia (28.0% each), fatigue (26.7%), and nausea (25.3%). Grade 3/4/5 TEAEs were reported in 73.3% of patients across all treatment groups; most common were neutropenia (20.0%), anemia (18.7%), and leukopenia (13.3%). Grade 3/4/5 ABBV-838–related TEAEs were reported by 40.0% of patients across all treatment groups. Overall, 4.0% of patients experienced TEAEs leading to death, none ABBV-838 related. The MTD was not reached; the selected recommended dose for the expansion cohort was 5.0 mg/kg Q3W. Pharmacokinetic analysis showed that exposure was approximately dose proportional. The overall response rate was 10.7%; very good partial responses and partial responses were achieved by 2 (2.7%) and 6 (8.0%) patients, respectively. Conclusions: These results demonstrate that ABBV-838 is safe and well-tolerated in patients with RRMM with a very limited efficacy.

Original languageEnglish
Pages (from-to)2308-2317
Number of pages10
JournalClinical Cancer Research
Volume26
Issue number10
DOIs
StatePublished - May 15 2020

Fingerprint

Dive into the research topics of 'First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma'. Together they form a unique fingerprint.

Cite this